Ferrer Completes Recruitment for PROSPER Phase II Trial in Progressive Supranuclear Palsy Ahead of Schedule Spanish multinational pharmaceutical company Ferrer has announced the successful completion of patient recruitment for the PROSPER study, a Phase II clinical trial investigating FNP-223, a…
Rigaku Establishes Technology Center in Taiwan to Strengthen R&D and Customer Support Rigaku Holdings Corporation, headquartered in Akishima, Tokyo, and led by CEO Jun Kawakami, has announced the establishment of Rigaku Technology Taiwan Co., Ltd. (RTTW), a new group company…
Enamine Plays Key Role in Discovery of Promising Broad-Spectrum Coronavirus Antiviral Enamine, a leading chemistry and R&D services company, has announced its pivotal contribution to the discovery of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. This milestone was achieved through…
IonQ Achieves Record-Breaking Quantum Computing Performance, Surpasses 99.99% Two-Qubit Gate Fidelity IonQ (NYSE: IONQ), a global leader in quantum computing, today announced a historic milestone in quantum technology: the company has achieved 99.99% two-qubit gate fidelity, setting a new world…
Bayer to Present Late-Breaking OCEANIC-STROKE Data at World Stroke Congress 2025 Bayer will present methods and baseline characteristic data from its global Phase III OCEANIC-STROKE study in a late-breaking presentation at the 17th World Stroke Congress (WSC 2025). The Congress…
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award…
the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance…
a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society…
a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at IDWeek 2025™ in Atlanta, Ga., by researchers from Columbia University Irving Medical Center show metagenomic sequencing that detects both RNA and DNA pathogens, available through Delve…
a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of…